BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Receives Consensus Recommendation of “Hold” from Analysts

Shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI) have been assigned a consensus rating of “Hold” from the seven brokerages that are covering the stock, MarketBeat Ratings reports. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $16.86.

A number of equities research analysts have recently weighed in on BTAI shares. Bank of America dropped their target price on BioXcel Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a report on Wednesday, March 13th. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 target price on shares of BioXcel Therapeutics in a report on Monday, March 18th. Canaccord Genuity Group decreased their target price on shares of BioXcel Therapeutics from $18.00 to $7.00 and set a “buy” rating on the stock in a research note on Thursday, March 14th. Finally, UBS Group reaffirmed a “neutral” rating and set a $4.00 price target (down previously from $9.00) on shares of BioXcel Therapeutics in a research note on Wednesday, February 21st.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC increased its stake in shares of BioXcel Therapeutics by 205.2% in the first quarter. Tower Research Capital LLC TRC now owns 1,529 shares of the company’s stock worth $29,000 after buying an additional 1,028 shares during the period. Northwestern Mutual Wealth Management Co. grew its stake in shares of BioXcel Therapeutics by 411.8% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,740 shares of the company’s stock worth $37,000 after acquiring an additional 1,400 shares during the period. Point72 Hong Kong Ltd purchased a new stake in BioXcel Therapeutics during the second quarter valued at $50,000. Quantbot Technologies LP purchased a new position in shares of BioXcel Therapeutics in the first quarter worth approximately $79,000. Finally, Barclays PLC increased its stake in shares of BioXcel Therapeutics by 533.3% in the 4th quarter. Barclays PLC now owns 5,136 shares of the company’s stock worth $111,000 after purchasing an additional 4,325 shares in the last quarter. Institutional investors own 30.68% of the company’s stock.

BioXcel Therapeutics Stock Performance

Shares of BTAI opened at $2.55 on Friday. The firm’s 50-day simple moving average is $2.88 and its 200 day simple moving average is $3.17. The firm has a market cap of $77.98 million, a P/E ratio of -0.41 and a beta of 0.40. BioXcel Therapeutics has a 52 week low of $1.91 and a 52 week high of $29.56.

BioXcel Therapeutics (NASDAQ:BTAI) last announced its earnings results on Tuesday, March 12th. The company reported ($0.76) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.98) by $0.22. The company had revenue of $0.38 million for the quarter, compared to analyst estimates of $1.17 million. BioXcel Therapeutics had a negative return on equity of 890.63% and a negative net margin of 12,974.86%. As a group, equities analysts forecast that BioXcel Therapeutics will post -2.52 earnings per share for the current year.

About BioXcel Therapeutics

BioXcel Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.